Cardiff Oncology, Inc.
Cardiff Oncology, Inc. (CRDF): 4 pipeline candidates · ~9 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
8.7 months
D/E 0.42 · 0% dilution
Lead: Phase 2
4 candidates
N/A
N/A
A transparent, data-derived signal for Cardiff Oncology, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$97.1M
Cash
$8.5M
Quarterly Burn
$12.3M
Runway
8.7 mo
Revenue
$41K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| eribulin | Phase 2 |
| evorpacept | Phase 2 |
| Onvansertib (Onv) | Phase 1 |
| vinorelbine | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
113
Total value held
$39.7M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 5,711,932 | $9.3M |
| blackrock, inc. | 3,981,387 | $6.4M |
| laurion capital management lp | 2,646,738 | $4.3M |
| acorn capital advisors, llc | 1,762,084 | $2.9M |
| geode capital management, llc | 1,599,663 | $2.6M |
| franklin resources inc | 1,205,803 | $2.0M |
| state street corp | 1,186,947 | $1.9M |
| flputnam investment management co | 595,127 | $964K |
| northern trust corp | 493,205 | $799K |
| vanguard fiduciary trust co | 446,225 | $723K |
Showing top 10 of 113 institutional holders of Cardiff Oncology, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Cardiff Oncology, Inc.'s pipeline?
Cardiff Oncology, Inc. (CRDF) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Cardiff Oncology, Inc.'s lead drug candidate?
Cardiff Oncology, Inc.'s most advanced tracked candidate is eribulin (Phase 2) for Breast Cancer, Metastatic.
What is Cardiff Oncology, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Cardiff Oncology, Inc. has approximately 8.7 months of cash runway.
What is Cardiff Oncology, Inc.'s market capitalization?
Cardiff Oncology, Inc.'s market capitalization is approximately $97.1M.
Who is the CEO of Cardiff Oncology, Inc.?
Dr. Mani Mohindru Ph.D. is the chief executive officer of Cardiff Oncology, Inc. (CRDF).
Get the full picture on Cardiff Oncology, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.